Agouron's Good News for Biotech
Using its red-hot shares to buy assets, Warner-Lambert is acquiring Agouron, a company with higher growth but the same P/E multiple--and thus bringing with it no dilution. Other major drug companies, enjoying similarly high valued shares largely on account of their size, not their pipelines, should consider the same cost-effective strategy.
You may also be interested in...
The EU’s Medical Device Regulation applies in just over a month’s time and the IVD Regulation in just over a year. But the standards underpinning them are way behind. Will they get the green light at last
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.
Amid a case of re-infection of a vaccinated healthcare worker in western China’s Xi’an city, and ongoing debate over domestic vaccines' efficacy, increasing attention is being paid in China to raising inoculation rates for COVID-19 and moving towards herd immunity.